Tosyl-L-lysine chloromethyl ketone | 2364-87-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Tosyl-L-lysine chloromethyl ketone
• 英文别名: N-[(3S)-7-amino-1-chloro-2-oxoheptan-3-yl]-4-methylbenzenesulfonamide
• CAS: 2364-87-6
• 化学式: C₁₄H₂₁ClN₂O₃S
• 分子量: 332.8
• InChiKey: RDFCSSHDJSZMTQ-ZDUSSCGKSA-N

物化性质

• 熔点：
  ~165 °C (dec.)
• 沸点：
  144°C (rough estimate)
• 密度：
  1.1784 (rough estimate)
• 溶解度：
  H2O:50 mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  21
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  97.6
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38

反应信息

• 作为反应物：
  描述：

  三羟甲基氨基甲烷盐酸盐 、 氯化钠 、 3-氟-4-甲氧基苯乙酮 、 antipain 、 苯甲基磺酰氟 、 Tosyl-L-lysine chloromethyl ketone 、 L-精氨酸,N-乙酰基-L-亮氨酰-L-亮氨酰- 、 胃酶抑素 A 、 N-[2-(Dimethylamino)ethyl]-2-(2-ethylbutoxy)-N-methyl-2,2-diphenylacetamide--hydrogen chloride (1/1) 在 G-Sepharose 、 N-[2-(Dimethylamino)ethyl]-2-(2-ethylbutoxy)-N-methyl-2,2-diphenylacetamide--hydrogen chloride (1/1) 、 sodium dodecyl-sulfate 作用下， 反应 1.25h， 生成 sodium dodecyl-sulfate
  参考文献：
  名称：

  ANTI-PHOSPHORYLATED TAU PROTEIN ANTIBODIES AND METHODS FOR DETECTING ALZHEIMER`S DISEASE WITH THE USE OF THE SAME

  摘要：

  一种抗体是通过使用含有成对螺旋丝内含有磷酸化tau蛋白的磷酸化位点的部分肽作为免疫原来制备的。然后，检查从怀疑患有阿尔茨海默病的个体中获取的样本与获得的抗体的反应性，以此来检测疾病。

  公开号：

  US20020086009A1

文献信息

• INHIBITORS OF POLYISOPRENYLATED METHYLATED PROTEIN METHYL ESTERASE
  申请人：Lamango Nazarius Saah

  公开号：US20090253640A1

  公开（公告）日：2009-10-08

  Inhibitors of the enzyme prenylated methylated protein methyl esterase (PMPMEase), the last step in the prenylation process for many eukaryotic proteins, having the general structure R 1 -X-A-B(R 2 )-Y or R 1 -X-A(R 2 )-B-Y, where R 1 is preferably a polyisoprenyl group, X is a linking group, Y is a group that promotes affinity interactions to the active site of PMPMEase and imparts hydrolysis resistance to the inhibitor, A and B are bridge atoms, and R 2 is a characteristic-providing substituent.

  抑制酶前醇基化蛋白甲基酯酶（PMPMEase）的化合物，这是许多真核蛋白质前醇化过程的最后一步，具有一般结构R1-X-A-B（R2）-Y或R1-X-A（R2）-B-Y，其中R1最好是多异戊烯基团，X是连接基团，Y是促进与PMPMEase活性位点的亲和作用并赋予抑制剂水解抗性的基团，A和B是桥接原子，R2是提供特征的取代基。
• Anaplasma marginale subunit antigen for vaccination and diagnosis
  申请人：WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION

  公开号：EP0196290A2

  公开（公告）日：1986-10-01

  Substantially pure antigenic surface proteins of Anaplasma marginale have been identified, and are capable of inducing immune responses in ruminants which neutralizes virulent Anaplasma marginale. The antigenic surface proteins have one or more components having a molecular weight of about 105,000 daltons, 86,000 daltons, 61,000 daltons, 36,000 daltons, 31,000 daltons, or 15,000 daltons, and can be purified by an immunoaffinity chromatography process comprising the steps of disrupting Anaplasma marginale initial bodies by treatment with a detergent, passing the disrupted initial bodies over a chromatography column comprising an insoluble matrix coupled to monoclonal anti- bodies against a determinant on said antigenic surface protein to selectively bind said antigenic surface protein to said monoclonal antibodies and recovering the bound substantially pure antigenic surface protein from said insoluble matrix. The antigens have further utility in diagnostic tests for anaplasmosis. They can be synthesized by polypeptide procedures or by genetic engineering.

  已鉴定出相当纯净的边疫疟原虫抗原表面蛋白，它们能够诱导反刍动物产生免疫反应，从而中和毒性边疫疟原虫。抗原表面蛋白具有一种或多种成分，其分子量约为 105,000 道尔顿、86,000 道尔顿、61,000 道尔顿、36,000 道尔顿、31,000 道尔顿或 15,000 道尔顿，可通过免疫亲和层析工艺纯化，该工艺包括以下步骤：用去污剂处理边缘疟原虫的初始体、将破坏的初始体通过色谱柱，色谱柱包括不溶性基质，该不溶性基质与针对所述抗原表面蛋白上的决定因子的单克隆抗体偶联，以选择性地将所述抗原表面蛋白与所述单克隆抗体结合，并从所述不溶性基质中回收结合的纯度相当高的抗原表面蛋白。抗原在无形体病的诊断检测中还有进一步的用途。它们可以通过多肽程序或基因工程合成。
• Novel fibrinolytic enzymes
  申请人：KabiGen AB

  公开号：EP0297066A1

  公开（公告）日：1988-12-28

  A fibrinolytically active plasminogen activator of the tissue type, wherein the growth factor (G) domain has been deleted, and wherein also the K1 domain has been deleted and additionally has been modified in one or more of the following sites or region: the sites of amino acid residues 177, 184, 277 and 448 and the F do­main, the F domain modification if present being a deletion of part or all of said domain;     DNA-sequence comprising a nucleotide sequence coding for said plasminogen activator;     expression vector which in a transformed host cell can express said DNA-sequence;     host cell transformed using such vector;     pharmaceutical composition comprising the fibrinolytically active plasminogen activator;     plasminogen activator for use in treating thrombotic disease;     a process for the manufacture of such fibrinolytically active plasminogen activator;     a process for the treatment of thrombotic disorder; and     a process of localizing thrombi while using such plasminogen activator.

  一种组织类型的具有纤溶活性的纤溶酶原激活剂，其中生长因子（G）结构域已被删除，K1结构域也已被删除，另外在以下一个或多个位点或区域进行了修饰：氨基酸残基177、184、277和448位点以及F结构域，F结构域的修饰（如果存在）是删除部分或全部所述结构域； DNA 序列，包括编码所述纤溶酶原激活剂的核苷酸序列； 表达载体，在转化的宿主细胞中可表达所述 DNA 序列； 使用这种载体转化的宿主细胞； 包含纤溶活性纤溶酶原激活剂的药物组合物； 用于治疗血栓性疾病的纤溶酶原激活剂； 一种制造这种纤溶活性纤溶酶原激活剂的工艺； 治疗血栓性疾病的工艺；以及 一种在使用这种纤溶酶原激活剂时定位血栓的工艺。
• Devices for treating disorders of a paranasal sinus
  申请人：Acclarent, Inc.

  公开号：EP2532383A2

  公开（公告）日：2012-12-12

  A catheter device (1000) for treating a disease or disorder of a paranasal sinus having an ostium which opens into said paranasal sinus, said device comprising: a catheter shaft (1002) having a distal end, said catheter shaft being suitable for advancing, distal end first, through the ostium and into the paranasal sinus; a distal balloon (1006) for positioning inside the paranasal sinus adjacent to the ostium; a proximal balloon (1004) for positioning outside the paranasal sinus adjacent to the ostium; and at least one balloon inflation lumen extending through the catheter shaft (1002) for inflation of said distal and proximal balloons (1006,1004), said device further comprising a lumen that is sized to receive a guidewire such that the device may be advanced over a guidewire.

  一种用于治疗副鼻窦疾病或失调的导管装置（1000），该副鼻窦具有开口进入所述副鼻窦的骨膜，所述装置包括：具有远端的导管轴 (1002)，所述导管轴适用于先将远端推进，穿过开口并进入副鼻窦；远端球囊 (1006)，用于定位在邻近开口的副鼻窦内；近端球囊 (1004)，用于定位在邻近开口的副鼻窦外；以及至少一个球囊充气管腔，该管腔延伸穿过导管轴 (1002)，用于对所述远端和近端球囊 (1006,1004) 进行充气，所述装置还包括一个管腔，该管腔的大小可接收导丝，从而使装置可在导丝上方推进。
• Paranasal sinus lavage device
  申请人：Acclarent, Inc.

  公开号：EP2535079A2

  公开（公告）日：2012-12-19

  A device for lavage of a paranasal sinus having an ostium, said device comprising: a catheter (1800,1900) having a proximal end, a distal end, an infusion lumen (1812,1902), an aspiration lumen (1810,1914), an infusion outlet aperture (1806,1904) and an aspiration inlet aperture (1808); and a balloon (1804,1912) for occluding a paranasal sinus ostium located on the catheter proximal to the infusion fluid outlet aperture and aspiration inlet aperture, whereby lavage fluid may be infused through the infusion lumen, out of the infusion outlet aperture and into the paranasal sinus and such lavage fluid may then be aspirated from the paranasal sinus through the aspiration inlet aperture and through the aspiration lumen.

  一种用于灌洗具有造口的副鼻窦的装置，所述装置包括导管 (1800,1900)，具有近端、远端、输液腔 (1812,1902)、吸液腔 (1810,1914)、输液出口孔 (1806,1904) 和吸液入口孔 (1808)；和一个气球（1804,1912），用于闭塞位于输液出口孔和吸液入口孔近端、导管上的副鼻窦骨膜，从而可通过输液腔、输液出口孔和副鼻窦输注灌洗液，然后可通过吸液入口孔和吸液腔从副鼻窦吸出灌洗液。